Natera and court rulings vs ArcherDx and Invitae

Natera is a leading company in the genetic diagnostics sector, offering a range of products for both non-invasive prenatal testing (NIPT) and cancer diagnostics. Their cancer Dx product, Signatera, is a sensitive molecular residual disease (MRD) assay that uses circulating tumor DNA (ctDNA) to detect cancer recurrence earlier than traditional methods.

Natera has been involved in several patent infringement lawsuits with competitors, and some of these cases have been recently resolved in Natera's favor. In a recent ruling, a US District Court for the District of Delaware ordered ArcherDx and Invitae to permanently stop using products containing material patented by Natera.

The court found that…